(Q36414027)

14 August 2017

Gastrointestinal malignancies harbor actionable MET exon 14 deletions (English)

1 reference

14 August 2017

2

Sai-Hong Ignatius Ou

0 references

author name string

Jeeyun Lee

1

1 reference

14 August 2017

Ji Min Lee

3

1 reference

14 August 2017

Hee Cheol Kim

4

1 reference

14 August 2017

Mineui Hong

5

1 reference

14 August 2017

Sun Young Kim

6

1 reference

14 August 2017

Jiryeon Jang

7

1 reference

14 August 2017

Soomin Ahn

8

1 reference

14 August 2017

So Young Kang

9

1 reference

14 August 2017

Sujin Lee

10

1 reference

14 August 2017

Seung Tae Kim

11

1 reference

14 August 2017

Bogyou Kim

12

1 reference

14 August 2017

Jaehyun Choi

13

1 reference

14 August 2017

Kyung-Ah Kim

14

1 reference

14 August 2017

Jiyun Lee

15

1 reference

14 August 2017

Charny Park

16

1 reference

14 August 2017

Se Hoon Park

17

1 reference

14 August 2017

Joon Oh Park

18

1 reference

14 August 2017

Ho Yeong Lim

19

1 reference

14 August 2017

Won Ki Kang

20

1 reference

14 August 2017

Keunchil Park

21

1 reference

14 August 2017

Young Suk Park

22

1 reference

14 August 2017

Kyoung-Mee Kim

23

1 reference

14 August 2017

language of work or name

English

0 references

publication date

10 September 2015

1 reference

14 August 2017

1 reference

14 August 2017

6

1 reference

14 August 2017

29

1 reference

14 August 2017

28211-28222

1 reference

Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors

14 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4695055

Comprehensive molecular profiling of lung adenocarcinoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4695055

Nanostring-based multigene assay to predict recurrence for gastric cancer patients after surgery

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4695055

Identification of MET genomic amplification, protein expression and alternative splice isoforms in neuroblastomas

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4695055

Cbl-independent degradation of Met: ways to avoid agonism of bivalent Met-targeting antibody

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4695055

A new anti-c-Met antibody selected by a mechanism-based dual-screening method: therapeutic potential in cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4695055

The transcriptional landscape and mutational profile of lung adenocarcinoma.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4695055

MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4695055

Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4695055

Genetic and structural variation in the gastric cancer kinome revealed through targeted deep sequencing

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4695055

Gastric cancer cell line Hs746T harbors a splice site mutation of c-Met causing juxtamembrane domain deletion

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4695055

Cell culture modeling of genotype-directed sensitivity to selective kinase inhibitors: targeting the anaplastic lymphoma kinase (ALK).

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4695055

Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4695055

Assessment of a HER2 scoring system for gastric cancer: results from a validation study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4695055

Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4695055

Somatic mutations lead to an oncogenic deletion of met in lung cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4695055

Identification of the major autophosphorylation site of the Met/hepatocyte growth factor receptor tyrosine kinase

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4695055

Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4695055

HER2-positive gastric cancer with concomitant MET and/or EGFR overexpression: a distinct subset of patients for dual inhibition therapy.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4695055

A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4695055

MET overexpression assessed by new interpretation method predicts gene amplification and poor survival in advanced gastric carcinomas

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4695055

21 September 2018

Identifiers

DOI

10.18632/ONCOTARGET.4721

1 reference

14 August 2017

1 reference

14 August 2017

PubMed publication ID

26375439

1 reference